Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Onglyza

- PMLiVE

AstraZeneca shares phase 3 results for Imfinzi plus Imdelltra in extensive-stage small cell lung cancer

Around 195,000 people globally will be treated for this form of lung cancer in 2026

- PMLiVE

AstraZenca’s Etcamah combination therapy given FDA Accelerated Approval for breast cancer

The approval was based on phase 3 trial results showing a 56% risk reduction in disease progression

- PMLiVE

FDA approves Priovant’s Lisraya for dermatomyositis

This is the first oral drug treatment for this rare disease in adults

- PMLiVE

Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine approved by US FDA

The 2026-2027 vaccine targets the XFG variant to more closely match current variants

- PMLiVE

Lilly to acquire Merida Biosciences in deal worth up to $2.875bn

The acquisition is to advance treatments for serious autoimmune and allergic diseases

- PMLiVE

AstraZeneca and Daiichi Sankyo’s Enhertu plus pertuzumab approved in EU as first-line treatment for breast cancer

This is the first new regimen in more than a decade for first-line treatment for this type of breast cancer

- PMLiVE

FDA grants Fast Track status for peanut allergy immunotherapy

The treatment uses peptides designed to retrain the immune system to tolerate peanuts

- PMLiVE

Eli Lilly’s Foundayo authorised by UK MHRA for weight loss and type 2 diabetes

The UK is the first country in Europe to authorise the oral medication

- PMLiVE

NICE recommends treatments for mantle cell lymphoma and chronic lymphocytic leukaemia

The treatments are for eligible adults in England and Wales

- PMLiVE

Lilly’s olomorasib gets FDA Breakthrough Therapy designation for pancreatic cancer

Around 60,000 people in the US get pancreatic cancer each year, with an estimated 50,000 deaths projected annually

- PMLiVE

Novartis’ Pluvicto approved by FDA for metastatic hormone-sensitive prostate cancer

More than 186,000 men are diagnosed each year with mHSPC globally

- PMLiVE

AstraZeneca’s Trixeo recommended by CHMP for approval in EU for asthma

Asthma affects over 360 million people worldwide, including over 40 million people in Europe

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links